Moon-Kyu Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6572397/publications.pdf

Version: 2024-02-01

40 1,103 17 32 g-index

40 and an arrange of the state of

40 40 40 1969 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Diabetes Fact Sheet in Korea, 2016: An Appraisal of Current Status. Diabetes and Metabolism Journal, 2018, 42, 415.	1.8	201
2	PPAR- \hat{l}^3 Activation Increases Insulin Secretion through the Up-regulation of the Free Fatty Acid Receptor GPR40 in Pancreatic \hat{l}^2 -Cells. PLoS ONE, 2013, 8, e50128.	1.1	88
3	Serum uric acid: A strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism: Clinical and Experimental, 2016, 65, 432-440.	1.5	75
4	Non-HDL-cholesterol/HDL-cholesterol is a better predictor of metabolic syndrome and insulin resistance than apolipoprotein B/apolipoprotein A1. International Journal of Cardiology, 2013, 168, 2678-2683.	0.8	70
5	Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. Diabetes Care, 2015, 38, 1245-1252.	4.3	63
6	Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: An analysis of 480 subjects. Diabetes Research and Clinical Practice, 2014, 104, 266-272.	1.1	54
7	Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. Journal of Endocrinology, 2014, 220, 117-128.	1.2	52
8	Relationship between serum bilirubin levels and cardiovascular disease. PLoS ONE, 2018, 13, e0193041.	1.1	42
9	Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Biochemical and Biophysical Research Communications, 2008, 367, 623-629.	1.0	38
10	Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. European Journal of Endocrinology, 2015, 173, 313-323.	1.9	37
11	A randomized, doubleâ€blind, placeboâ€controlled, phase II clinical trial to investigate the efficacy and safety of oral DAâ€1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes/Metabolism Research and Reviews, 2015, 31, 295-306.	1.7	34
12	Efficacy and safety of ipragliflozin as an addâ€on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 2408-2415.	2.2	30
13	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase l– <scp>III</scp> clinical trials. Journal of Diabetes Investigation, 2019, 10, 418-428.	1.1	27
14	Cardiovascular disease incidence, mortality and case fatality related to diabetes and metabolic syndrome: A communityâ€based prospective study (<scp>A</scp> nsungâ€ <scp>A</scp> nsan cohort) Tj ETQq0	0 0 . æBT /	Ovæslock 10 T
15	Metabolic Syndrome and Cardiovascular Diseases in Korea. Journal of Atherosclerosis and Thrombosis, 2014, 21 Suppl 1, S31-S35.	0.9	25
16	Change in serum albumin concentration is inversely and independently associated with risk of incident metabolic syndrome. Metabolism: Clinical and Experimental, 2016, 65, 1629-1635.	1.5	24
17	The Effect of Continuous Ambulatory Peritoneal Dialysis on Change in Serum Leptin. Peritoneal Dialysis International, 1999, 19, 172-175.	1.1	21
18	Sex Factors in the Metabolic Syndrome as a Predictor of Cardiovascular Disease. Endocrinology and Metabolism, 2014, 29, 522.	1.3	18

#	Article	IF	CITATIONS
19	Delayed heart rate recovery after exercise as a risk factor of incident type 2 diabetes mellitus after adjusting for glycometabolic parameters in men. International Journal of Cardiology, 2016, 221, 17-22.	0.8	17
20	Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial. Diabetes and Metabolism Journal, 2017, 41, 135.	1.8	14
21	Validation of Risk Prediction Models for Atherosclerotic Cardiovascular Disease in a Prospective Korean Community-Based Cohort. Diabetes and Metabolism Journal, 2020, 44, 458.	1.8	14
22	Autonomic dysfunction, diabetes and metabolic syndrome. Journal of Diabetes Investigation, 2021, 12, 2108-2111.	1.1	14
23	Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, activeâ€controlled, randomized, doubleâ€blind study with openâ€label extension (the EVERGREEN study). Diabetes, Obesity and Metabolism, 2020, 22, 1527-1536.	2.2	13
24	Association of Body Mass Index with the Risk of Incident Type 2 Diabetes, Cardiovascular Disease, and All-Cause Mortality: A Community-Based Prospective Study. Endocrinology and Metabolism, 2020, 35, 416-424.	1.3	13
25	Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial. Diabetes and Metabolism Journal, 2019, 43, 422.	1.8	10
26	Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, doubleâ€blind, nonâ€inferiority trial. Diabetes, Obesity and Metabolism, 2019, 21, 631-639.	2.2	10
27	Baseline level and change in serum albumin concentration and the risk of incident type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 61-66.	1.2	9
28	Delayed heart rate recovery after exercise predicts development of metabolic syndrome: A retrospective cohort study. Journal of Diabetes Investigation, 2022, 13, 167-176.	1.1	8
29	Glucagon/insulin ratio in preoperative screening before pancreatic surgery: correlation with hemoglobin A1C in subjects with and without pancreatic cancer. Endocrine, 2014, 47, 493-499.	1.1	7
30	Diabetes and COVID-19: IDF perspective in the Western Pacific region. Diabetes Research and Clinical Practice, 2020, 166, 108278.	1.1	7
31	East Asian dietâ€mimicking diet plan based on the Mediterranean diet and the Dietary Approaches to Stop Hypertension diet in adults with typeÂ2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation, 2021, 12, 357-364.	1.1	7
32	Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study. Journal of Korean Medical Science, 2019, 34, e117.	1.1	7
33	Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes and Metabolism Journal, 2020, 44, 78.	1.8	7
34	Glucolipotoxicity and GLP-1 secretion. BMJ Open Diabetes Research and Care, 2021, 9, e001905.	1.2	5
35	Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. International Journal of Clinical Practice, 2017, 71, e12987.	0.8	4
36	Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC). Journal of Cellular Physiology, 2021, , .	2.0	4

#	Article	IF	CITATIONS
37	Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. Diabetes and Metabolism Journal, 2021, 45, 933-947.	1.8	3
38	Effect of Blood Pressure on Cardiovascular Diseases at 10-Year Follow-Up. American Journal of Cardiology, 2019, 123, 1654-1659.	0.7	2
39	Blood glucose control: Where are we?. Journal of Diabetes Investigation, 2021, 12, 1762-1764.	1.1	2
40	Introduction: Real-World Evidence in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 29-32.	1.2	1